OBR Daily Commentary

forumImage

Imfinzi And Tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit In POSEIDON Trial For 1st-line Stage IV Non-small Cell Lung Cancer

(AstraZeneca) May 7, 2021 - POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). Positive high-level results from the final analysis of POSEIDON showed the combination of Imfinzi, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone.

Read Article arrow

H. Jack West, MD (Posted: May 07, 2021)

quotesThe oncologic embodiment of a Pyrrhic victory. With these data, the combination of durvalumab with tremelimumab has the opportunity to become an inconsequential additional alternative that provides no advantage over many better established options in this setting that are destined to be higher choices. We even already have another PD-1/CTLA-4 inhibitor combination with nivolumab/ipilimumab that has a proven OS benefit over chemo alone in this setting, and which is already FDA approved (for patients with PD-L1 1% or higher) but has almost no use because it offered no clear incremental benefit over the far preferred option of chemo/pembrolizumab for a broad population of patients in the first-line setting. It will be interesting to see what AZ does with this, because I don't think marketing efforts will be covered by the 0.2% of the market it will capture.quotes

Add Comment 1 Comment
forumImage

Roche’s Tecentriq Approved By European Commission As A First-line Monotherapy Treatment For People With A Type Of Metastatic Non-small Cell Lung Cancer

(Roche) May 5, 2021 - Roche today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. “We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.”

Read Article arrow

H. Jack West, MD (Posted: May 05, 2021)

quotesA fine alternative to pembrolizumab, which is the current standard of care in this setting after establishing a clear and sustained survival benefit over chemotherapy in the KEYNOTE-024 trial, but a lateral move that offers no incremental benefit over what we already have with pembrolizumab in this setting.quotes

Add Comment 1 Comment
forumImage

Takeda Closes in on Potential Approval for NSCLC Drug, Mobocertinib

(BioSpace) Apr 28, 2021 - Takeda’s non-small cell lung cancer (NSCLC) treatment Mobocertinib (TAK-788) is leading closer to regulatory approval after the U.S. Food and Drug Administration granted priority review to the New Drug Application. The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date for Oct. 26.

Read Article arrow

H. Jack West, MD (Posted: May 01, 2021)

quotesMobocertinib doesn't offer activity at a level of osimertinib for EGFR mutated NSCLC or alectinib for ALK-positive NSCLC, and it presents some challenges in terms of tolerability, but it fulfills a real unmet need for this patient population. I know I and my patients with advanced NSCLC harboring an EGFR exon 20 insertion mutation would welcome having it approved and commercially available.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...